Similarly, we observed that high TET1 expression was significantly (p = 0.00045) associated with shortened PFS (14 months) compared with patients with lower TET1 expression (18 months) in serous carcinoma patients. This evidence concerns the gene TET1 and serous adenocarcinoma.